Table 1 Patient demographics and clinicopathological characteristics for Stage I, II, III patients with HER2-positive breast cancer
| At time of diagnosis of index cancer | ||||
|---|---|---|---|---|
|
Variable N (%) |
Total (N = 3394) |
HR-positive (n = 2015) |
HR-negative (n = 1379) | P-value |
| Age, mean (se), y | 52.48 (0.21) | 52.41 (0.29) | 52.59 (0.32) | |
| Age category, N, (%) | <.001 | |||
| 0 to <50 | 1,514 (45) | 931 (46) | 583 (42) | |
| 50 to <70 | 1,547 (46) | 865 (43) | 682 (49) | |
| 70+ | 333 (10) | 219 (11) | 114 (8) | |
| Race/Ethnicity, N, (%) | 0.030 | |||
| African-American | 259 (8) | 135 (7) | 124 (9) | |
| Caucasian | 2,693 (79) | 1,627 (81) | 1,066 (77) | |
| Hispanic | 262 (8) | 155 (8) | 107 (8) | |
| Asian Pacific Island | 126 (4) | 64 (3) | 62 (5) | |
| American Indian | 10 (<1) | 4 (<1) | 6 (<1) | |
| Other | 16 (<1) | 10 (1) | 6 (<1) | |
| Unknown | 28 (1) | 20 (1) | 8 (1) | |
| Menopausal Status, N, (%) | 0.001 | |||
| Premenopausal | 1,569 (46) | 978 (49) | 591 (43) | |
| Postmenopausal | 1,825 (54) | 1,037 (51) | 788 (57) | |
| Body Mass Index kg/m2, N, (%) | 0.512 | |||
| <18.5 kg/m2 (Underweight) | 52 (2) | 34 (2) | 18 (1) | |
| 18.5 to <25 kg/m2 (Normal) | 1,263 (37) | 750 (37) | 513 (37) | |
| 25 to <30 kg/m2 (Obese) | 913 (27) | 554 (27) | 359 (26) | |
| >30 kg/m2 (Severely Obese) | 884 (26) | 506 (25) | 378 (27) | |
| Missing/unknown | 282 (8) | 171 (8) | 111 (8) | |
| Co-morbidity score, N, (%) | 0.958 | |||
| 0 | 2,713 (80) | 1,609 (80) | 1,104 (80) | |
| 1 | 452 (13) | 271 (13) | 181 (13) | |
| 2+ | 229 (7) | 135 (7) | 94 (7) | |
| Method of detection, N, (%) | <.001 | |||
| Abnormal screening mammogram | 1,209 (36) | 755 (37) | 454 (33) | |
| Symptom | 2,012 (59) | 1,175 (58) | 837 (61) | |
| Other | 147 (4) | 67 (3) | 80 (6) | |
| Unknown | 26 (1) | 18 (1) | 8 (1) | |
| T stage, category, N, (%) | <.001 | |||
| T1 | 1,753 (52) | 1,103 (55) | 650 (47) | |
| T2 | 1,150 (34) | 691 (34) | 459 (33) | |
| T3 | 244 (7) | 129 (6) | 115 (8) | |
| T4 | 197 (6) | 73 (4) | 124 (9) | |
| Unknown | 50 (1) | 19 (1) | 31 (2) | |
| Nodal status, N, (%) | <.001 | |||
| Positive | 1,623 (48) | 907 (45) | 716 (52) | |
| Negative | 1,757 (52) | 1,101 (55) | 656 (48) | |
| Unknown | 14 (<1) | 7 (<1) | 7 (<1) | |
| AJCC stage, N, (%) | <.001 | |||
| I | 1,187 (35) | 772 (38) | 415 (30) | |
| II | 1,467 (43) | 887 (44) | 580 (42) | |
| III | 740 (22) | 356 (18) | 384 (28) | |
| Histologic grade, N, (%) | <.001 | |||
| Low/Intermediate | 907 (27) | 719 (36) | 188 (14) | |
| High | 2,324 (68) | 1,211 (60) | 1,113 (81) | |
| Unknown | 163 (5) | 85 (4) | 78 (6) | |
| Histology, N, (%) | <.001 | |||
| Invasive ductal | 3,101 (91) | 1,772 (88) | 1,329 (97) | |
| Invasive lobular | 105 (3) | 89 (4) | 16 (1) | |
| Mixed ductal and lobular | 139 (4) | 120 (6) | 19 (1) | |
| Other | 49 (1) | 34 (2) | 15 (1) | |
| LVI, N, (%) | 0.630 | |||
| Presence | 1,164 (34) | 678 (34) | 486 (35) | |
| Absence | 2,113 (62) | 1,267 (63) | 846 (61) | |
| Unknown | 117 (3) | 70 (3) | 47 (3) | |
| EIC, N, (%) | 0.536 | |||
| Presence | 606 (18) | 353 (18) | 253 (18) | |
| Absence | 2,788 (82) | 1,662 (82) | 1,126 (82) | |
| In patients with documented recurrence | ||||
| Variable |
Total
N = 458 |
HR-positive
N = 208 |
HR-negative
N = 250 | P -value |
| Disease free interval median (range), y | 1.95 (7.69) | 2.24 (7.69) | 1.70 (7.08) | |
| Age, mean (se), y | 50.95 (0.60) | 50.39 (0.94) | 51.41 (0.78) | |
| Race/Ethnicity, N, (%) | 0.644 | |||
| African-American | 51 (11) | 21 (10) | 30 (12) | |
| Caucasian | 358 (78) | 166 (80) | 192 (77) | |
| Hispanic | 31 (7) | 12 (6) | 19 (8) | |
| Asian Pacific Island | 12 (3) | 6 (3) | 6 (2) | |
| American Indian | 1 (<1) | 1 (<1) | 0 (0) | |
| Other | 4 (1) | 1 (<1) | 3 (1) | |
| Unknown | 1 (<1) | 1 (<1) | 0 (0) | |
| Menopausal status at time of diagnosis of index cancer, N, (%) | 0.207 | |||
| Premenopausal | 223 (49) | 108 (52) | 115 (46) | |
| Postmenopausal | 235 (51) | 100 (48) | 135 (54) | |
| Co-morbidity score at time of diagnosis of index cancer, N, (%) | 0.437 | |||
| 0 | 371 (81) | 166 (80) | 205 (82) | |
| 1 | 57 (12) | 25 (12) | 32 (13) | |
| 2+ | 30 (7) | 17 (8) | 13 (5) | |
| AJCC stage at time of diagnosis of index cancer, N, (%) | 0.437 | |||
| I | 77 (17) | 36 (17) | 41 (16) | |
| II | 188 (41) | 91 (44) | 97 (39) | |
| III | 193 (42) | 81 (39) | 112 (45) | |
| Histologic grade at time of diagnosis of index cancer, N, (%) | 0.016 | |||
| Low/Intermediate | 65 (14) | 40 (19) | 25 (10) | |
| High | 379 (83) | 163 (79) | 216 (86) | |
| Unknown | 14 (3) | 5 (2) | 9 (4) |